Jose Manuel T. P.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase 3 Randomized Open-Label Trial of OSE2101 Versus Docetaxel in HLA-A2 Positive Metastatic NSCLC Patients with Secondary Resistance to Immune Checkpoint Inhibitors
- Phase 3 Randomized Study of Petosemtamab and Pembrolizumab in First-Line Treatment of Recurrent/Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
- Phase 3 Study of Acasunlimab and Pembrolizumab Versus Docetaxel in PD-L1 Positive Metastatic NSCLC Post PD-1/PD-L1 Inhibitor and Platinum Chemotherapy
Data & Insights
Has run more than one trial at 55 of 228 partner sites.
Specializations
Head and Neck Cancer
This investigator specializes in treating recurrent and metastatic head and neck squamous cell carcinoma, with particular focus on PD-L1 positive tumors. Their research explores innovative combination therapies involving immunotherapy approaches for first-line treatment.
- Advanced HNSCC Management
- Immunotherapy Combinations
- PDL1-targeted Treatments
Lung Cancer
The investigator has extensive experience in treating metastatic non-small cell lung cancer, particularly focusing on advanced therapeutic strategies. Their work encompasses both second and third-line treatments, including therapeutic cancer vaccines and novel drug combinations.
- Advanced NSCLC Treatment
- Post-immunotherapy Care
- HLA-A2 Positive NSCLC
Melanoma
The investigator's work extends to treating advanced melanoma, with specific expertise in managing unresectable and metastatic cases. Their research includes evaluating novel therapeutic approaches and biosimilar treatments.
- Advanced Melanoma Management
- Biosimilar Therapeutics
- Combination Treatment Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.